Considerations for the New Four-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB in the U.S.

Date: September 21, 2021
Time: 2:00 - 3:30 pm Eastern
Location: Online

COURSE DESCRIPTION & OVERALL GOAL
This webinar will review the results and implications of the landmark open-label trial, Study 31/A5349. The webinar will outline the methods and findings of the study and provide an overview of best practices and considerations for implementing this shorter-course regimen in TB programs in the US. The format will include didactic presentations followed by a moderated discussion and Q&A.

WHO SHOULD ATTEND
The webinar is open to physicians, nurses, public health staff, and other health care workers who manage patients at risk for or diagnosed with TB infection or disease.

WHY COURSE IS NEEDED
Awareness of new drug-regimens and treatment options and the practical implications of new regimens for TB programs are essential to effectively address TB prevention and control needs. This educational activity will assist TB providers and programs with summarizing and interpreting the results of the open-label trial Study 31/A5349, and opportunities for use of a 4-month TB regimen, including ongoing research on the use of the regimen in special populations. The methods, results, interpretation of results, findings for subgroups and recommendations for monitoring this drug regimen will be highlighted.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able:

• Outline the results of the Study 31 Trial and potential opportunities for future use of shortened TB treatment regimens.  
• Describe the non-inferiority approach used in the Study 31 trials and the implication for interpreting results in the U.S.
• Summarize how the results of the Study 31 trials apply to subgroups, including current research that will further inform study subgroups.

COURSE REQUIREMENTS
In order to meet the learning objectives and receive continuing education credits, participants are required to attend the webinar and complete an evaluation.

CONTINUING EDUCATION INFORMATION
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and the Tuberculosis Centers of Excellence for Training, Education, and Medical Consultation. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: This activity is awarded 1.5 contact hour (60 minute CH). Nurses should only claim those contact hours actually spent participating in the activity.

REGISTRATION INFORMATION
There is no charge to attend this webinar but pre-registration is mandatory. Registration is available here.

There is limited space for the webinar and acceptance will be on a firstcome, first-serve basis. For additional information, please contact Olivia Dupont at od94@njms.rutgers.edu

FUNDING DISCLOSURE
Funding for this course was made possible in part by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government.